Renalytix AI has appointed Patti Connolly as vice president of clinical and scientific affairs and Paul Brenner, Ph.D. to the Advisory Board.
The Cardiff-headquartered, AIM-listed company develops its technology to treat the disease, and support in diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery.
Brenner is a computer science faculty member at the University of Notre Dame and Associate Director of Notre Dame’s Center for Research Computing, to its Advisory Board.
Brenner contributes deep expertise in advanced computation, artificial intelligence and cyber security to the RenalytixAI Advisory Board.
In his role at the University of Notre Dame, Brenner advances computation-based research through cyber system security, design, deployment and operation, and directs a team of technical experts in the operation of high-performance computing hardware and software infrastructure for an active user base of over 2,000 researchers.
He also serves as a Senior Reserve Advisor to the Air Force Cyber College Commandant (AFCC). In this capacity he advises the AFCC leadership on military reserve matters and leads the provision of technical and operational capabilities to AFCC.
Connolly brings over two decades of leadership experience in clinical research and development, the past ten years of which have focused on managing successful clinical trials as well as domestic and international regulatory affairs initiatives.
Connolly served as clinical services director at Pearl Pathways where she was responsible for all clinical services operations, the full-service contract research organisation and the institutional review board.